Appointments at Teva, Codexis, Albemarle and BayBio – People on the move
Phillip Frost has been named as chairman of the board of directors at Teva. Frost was chairman and CEO of Ivax until it was acquired by Teva in 2006. Since then he has served as vice chairman. Moshe Many, Teva’s interim chairman, will now serve as vice chairman.
Codexis has appointed Vonnie Estes as vice president (VP), strategic planning, technology. Estes has 20 years experience at global chemical companies, including DuPont, Monsanto and Syngenta.
Luke Kissam has been elected as president of Albemarle. Kissam joined Albemarle as VP, general counsel and secretary in 2003 and since then has held several roles of increasing responsibility, culminating in the post of SVP, manufacturing and law.
Cerulean Pharma has named John Ryan as SVP, chief medical officer and Karen Roberts as SVP, finance and administration. During his 20 year career Ryan has worked at AVEO Pharmaceuticals, Wyeth and Merck Research Laboratories.
Roberts joins Cerulean from Elixir Pharmaceuticals. Before joining Elixir in 2001 Roberts worked at Frontline Group, Dyax Corporation and T Cell Sciences.
Jeremy Leffler has joined BayBio as chief operating officer. Leffler has political experience, including representing Eli Lilly in Washington DC, and this could be significant as BayBio attempts to grow California’s biotech sector at a time when the state is struggling financially.
Endo Pharmaceuticals has named Julie McHugh as chief operating officer. Most recently, McHugh was CEO of Nora Therapeutics and has also worked at Johnson & Johnson, Astra-Merck, SmithKline and Rhone-Poulenc Rorer.
Fred Hassan, who was CEO of Schering-Plough until its merger with Merck & Co, has been appointed chairman of the board at Bausch & Lomb. The company has also named Brent Saunders as CEO.
